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13.12.001Abstract Many cancers apparently showing similar phenotypes are actually distinct at the molecu-
lar level, leading to very different responses to the same treatment. It has been recently demonstrated
that pathway-based approaches are robust and reliable for genetic analysis of cancers. Nevertheless,
it remains unclear whether such function-based approaches are useful in deciphering molecular
heterogeneities in cancers. Therefore, we aimed to test this possibility in the present study. First,
we used a NCI60 dataset to validate the ability of pathways to correctly partition samples. Next,
we applied the proposed method to identify the hidden subtypes in diffuse large B-cell lymphoma
(DLBCL). Finally, the clinical signiﬁcance of the identiﬁed subtypes was veriﬁed using survival anal-
ysis. For the NCI60 dataset, we achieved highly accurate partitions that best ﬁt the clinical cancer
phenotypes. Subsequently, for a DLBCL dataset, we identiﬁed three hidden subtypes that showed
very different 10-year overall survival rates (90%, 46% and 20%) and were highly signiﬁcantly
(P= 0.008) correlated with the clinical survival rate. This study demonstrated that the pathway-
based approach is promising for unveiling genetic heterogeneities in complex human diseases.g Y), raoshaoq@gdmc.edu.cn
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Genetic heterogeneity has attracted increasing attention in the
study of genetic mechanisms of complex diseases. It describes
the biological complexities that apparently similar characters
may result from different genes or different genetic mecha-
nisms [1]. In the clinical setting, patients with diseases
displaying a similar phenotype but resulting from different
genetic causes frequently respond very differently to the samecademy of Sciences and Genetics Society of China. Production and hosting
32 Genomics Proteomics Bioinformatics 12 (2014) 31–38treatment and thus receive a markedly different prognosis.
Therefore, elucidation of the genetic heterogeneities underlying
complex diseases has profound inﬂuences on both modern
clinical practice and basic biomedical research.
Rapidly accumulated genomic-scale molecular data provide
good opportunities to unveil the genetic heterogeneities in
complex diseases at the molecular level. Signiﬁcant improve-
ments in methods and applications for analysis of the genetic
heterogeneity have been achieved in the past decades. The use-
fulness of large-scale gene expression data, as measured by
microarrays, has noticeably been indicated by the successful
stratiﬁcation of diffuse large B-cell lymphoma (DLBCL)
[2–5]. In these pioneering studies, an unsupervised clustering
algorithm was used to partition both gene expression data
and patients with an aim to deﬁne genetically homogeneous
novel cancer subgroups among cancer patients based on the
principle that patients within the same cluster probably involve
the similar molecular pathogenesis and hence could be
grouped into the same molecular subphenotype [6]. Although
the traditional clustering analysis based on individual gene
expression proﬁles has achieved great success in unveiling the
genetic heterogeneity, it seldom considered the combined ac-
tions of multiple functionally dependent genes. It is increas-
ingly recognized that complex diseases such as cancers are a
consequence of alterations in a complicated cascade of events
involving multiple biological processes and pathways. Thus,
subtypes identiﬁed by individual genes often lack good biolog-
ical interpretations. In this sense, the development of function-
based methods for cancer subtyping is warranted.
Gene Ontology (GO) [7] and the Kyoto Encyclopedia of
Genes and Genomes (KEGG) [8] are the two most common
databases currently used for gene functional annotation. GO
terms are used primarily for the annotation of individual gene
products, whereas KEGG pathway terms are used for the
annotation of classes of gene products, thus providing a more
precise delineation of functionalities for a group of genes that
act together to some extent. KEGG pathway is a collection of
manually drawn pathway maps that represent the knowledge
on molecular interactions and reaction networks for human
diseases, environmental information processing, genetic infor-
mation processing, etc., thus possibly providing biological
interpretations of higher-level systemic functions [9]. Hence,
a pathway-based approach can integrate the effects of genetic
factors and biological networks [10] and has been used for dis-
ease classiﬁcation [11]. In our previous work [1], we proposed a
GO-based approach to unveil the hidden heterogeneities in
cancers, and demonstrated that it can successfully integrate
the cellular function and the gene expression proﬁle, and the
approach showed the greater advantage of GO in classifying
the cancer types. In principle, a similar pathway-based ap-
proach should have comparable performance in the genetic
analysis of molecular heterogeneities in cancers. Numerous
studies have shown that the cancer subtypes are, in essence,
related to multiple pathways [12–14]. For example, recent
evidence has shown that molecular subtypes of DLBCL arise
from distinct genetic pathways [15]. Therefore, this study
aimed to verify whether a pathway-based approach is useful
in deciphering molecular heterogeneities in complex diseases
such as cancer.
In this study, we proposed a pathway-based clustering
approach to unveil disease heterogeneities based on multiple
pathways. First, we selected differentially expressed genes thatare associated with speciﬁc disease conditions. It should be
noted that algorithms such as the t test or F test are not proper
for selecting differentially expressed genes due to the presence
of genetic heterogeneity, because the validity of these tests re-
lies on accurately and unambiguously deﬁning phenotype
characteristics. Hence, we took a robust metric, the overall
variability of gene expression, to guide gene selection. Firstly,
genes with top-ranked expression variations across samples,
which explain most of the total variance potentially contrib-
uted by known or unknown factors (for example, the hidden
cancer subtypes), were selected as ‘‘feature genes’’ in the initial
gene selection as implemented in several previous studies
[16,17]. Then, we identiﬁed KEGG pathways enriched with
feature genes as ‘‘putative signature pathways’’ (here, ‘‘en-
riched’’ means that a pathway has saliently more feature genes
(with large variance) than a random gene set of the same size
does). Finally, we classiﬁed samples to identify the hidden dis-
ease subtypes using the expression proﬁles of genes annotated
to these well-characterized pathways. In the numerical analy-
sis, we ﬁrst validated the proposed approach in accurately
partitioning cancer phenotypes using a publicly-available large
cancer dataset. Subsequently, we used the approach to identify
the hidden subtypes of a notoriously heterogeneous pheno-
type, DLBCL. Our results demonstrated that three new
subtypes identiﬁed using signature pathways had very different
10-year overall survival rates, and the partitions were highly
signiﬁcantly correlated with the clinical survival rates.Results
Validation of the proposed pathway-based approach using a
large microarray dataset
We selected the signature pathways that were signiﬁcantly
(FDR 6 0.01, see the Materials and methods section for the
details) enriched with the 10% top-ranked genes with largest
expression variances based on the NCI60 dataset [18]. As a re-
sult, three pathways were identiﬁed, which were used for the
subsequent analyses. These include the small cell lung cancer
pathway (hsa05222), the extracellular matrix (ECM)–receptor
interaction pathway (hsa04512) and the focal adhesion path-
way (hsa04510) (Table 1). First, we evaluated the ability of
each signature pathway to accurately partition the samples
into the known cancer types using the clustering analysis based
on only the expression proﬁles of genes within the pathway.
Our results based on each of the three pathways agreed well
with the original clinical labels. The observed values for the
adjusted Rand index (ARI) [19] (to measure the agreement
between the identiﬁed clusters and the original partitions,
ranging from 0 to 1, see the Materials and methods section
for the details) were 0.83, 0.69 and 0.78, respectively. Subse-
quently, to determine the empirical signiﬁcance of each
pathway, we randomly selected 1000 gene subsets of the same
pathway size from the null distribution as described in the
Materials and methods section. No random subset achieved
an ARI value higher than that of the corresponding pathway
such that all identiﬁed signature pathways showed signiﬁcantly
better performance (P< 0.001) in correctly partitioning the
samples (that is, more likely relevant to the phenotypic parti-
tions). Furthermore, after applying the majority rule voting
for integrating results from the three signature pathways, we
Table 1 Signature pathways for NCI60
Signature pathway Number of
annotated genes
Nominal P
(pathway)a
FDR
(pathway)b
ARI Number of misallocated
samples
P
(ARI)c
hsa05222: small cell lung
cancer
19 7.83E06 9.82E03 0.83 2 <0.001
hsa04512: ECM–receptor
interaction
21 3.03E07 3.81E04 0.69 8 <0.001
hsa04510: focal adhesion 36 1.54E10 1.93E07 0.78 3 <0.001
Note: Signature pathways for NCI60 were identiﬁed by using FDR for multiple tests correction (adjusted a= 0.01). Details of the NCI60 dataset
were described previously [18]. a Modiﬁed Fisher Exact P value. b FDR stands for false positive rate, which is used for adjustment of multiple tests
for 201 pathways. c Statistical signiﬁcance of ARI for the selected pathway. ARI stands for adjusted Rand index.
Zhao X et al / Pathway-based Analysis of Heterogeneities 33achieved a ARI value of 0.83, with only two tumor samples
misallocated. Alternatively, four samples were misclassiﬁed
with construction of a decision tree (Figure 1).
We also assessed the robustness of the proposed pathway-
based approach to the methods for feature gene selection.
With the feature genes selected as the top 10%, 15% and
20% ranked genes with the largest variances, we found that
the identiﬁed signature pathways largely overlapped. Com-
pared to using the top 10% ranked genes as feature genes,
no additional pathways were identiﬁed when using the top
15% genes, and only one more pathway was identiﬁed when
using the top 20% genes. These data suggest the robustness
of such pathways to the differences of the thresholds for select-
ing feature genes. Numerous biological experiments provided
ample evidence to support the involvement of the three path-
ways in the molecular mechanisms underlying the various can-
cer types. For example, the focal adhesion pathway and the
ECM–receptor interaction pathway were identiﬁed to be the
functional gene sets that were signiﬁcantly differentially ex-
pressed in leukemia [20]. In addition, by searching for the
oncogenes in the KEGG database, one can easily ﬁnd that
the three pathways, particularly the small cell lung cancer
pathway and the focal adhesion pathway, were enriched with≤ 0.385
> 0.573 ≤ 0.573
≤ 0.374> 0.374
> 0.385 ≤ 1.053> 1.053
hsa04512
hsa05222
hsa04510
hsa05222
Renal cancer
(9/2)
Central nervous 
system cancer
(4/0)
Melanoma
(8/1)
Colon cancer
(7/0)
Leukemia
(7/1)
Figure 1 Decision tree based on three signature pathways for ﬁve
cancer types
The internal nodes of the tree are the signature pathways. The leaf
nodes represent the classiﬁcation for ﬁve types of cancer (renal
cancer, central nervous system cancer, melanoma, colon cancer
and leukemia). Included in the leaf nodes are the total number of
samples over the number of the incorrectly predicted samples for
the speciﬁc type of cancer indicated.various oncogenes. All evidence supports that these three path-
ways are truly linked to cancer(s).
Unveiling the hidden genetic heterogeneities in DLBCL
The genetic heterogeneities in DLBCL have been extensively
investigated previously [2,21,22]. Inspired by its success in clas-
sifying the known NCI60 cancer types, we then applied the
proposed pathway-based approach to discover the hidden
molecular types of DLBCL.
Based on the DLBCL dataset [2], we identiﬁed three sub-
types using two signature pathways, i.e., the hematopoietic cell
lineage pathway (has04640) and the cytokine receptor interac-
tion pathway (has04060) (Table 2). These two pathways might
be substantially responsible for the incidence and progression
of DLBCL. The former pathway was associated with the im-
mune system, and latter pathway was associated with various
signaling molecules and their corresponding interactions. The
abnormalities in either the immune function and/or the signal-
ing molecules and their interactions were considered to be the
major causes of DLBCL [23]. The sensitivity analysis based on
different criteria for feature gene selection (top 10%, 15% and
20% ranked genes with the largest variances) revealed that the
identiﬁed signature pathways largely overlapped. Compared to
using the top 10% ranked genes as feature genes, two addi-
tional pathways were identiﬁed when using the top 15% genes,
and only one more pathway was identiﬁed when using the top
20% genes. Thus, only the results for the criterion of the top
10% ranked genes were presented in this study.
The survival results for these subtypes are shown in
Figure 2. The 10-year overall survival rates for three newly
deﬁned molecular subtypes were 90%, 46% and 20%, respec-
tively. The log-rank statistic showed that the survival time of
the three subtypes was signiﬁcantly different (P= 0.008),
which had a markedly higher caliber compared to the original
partitions (the clinic labels, P= 0.010, see [2]) to map their dif-
ferential survival proﬁles. Compared with the partitioning re-
sults from a GO module (P= 0.007) obtained previously by
our group [1], the pathway-based approach performed equally
well, and identiﬁed one more molecular subtype.
To further explore a compact model for clinical use, we ana-
lyzed genes included in the two signature pathways using Cox
proportional-hazards models. In the univariate analysis, nine
genes were found at the liberal signiﬁcance level of 0.1. Subse-
quently, using the stepwise variable selection option (with the
same inclusion and exclusion P values of 0.05) for the multivar-
iate Cox proportional-hazards regression model, we identiﬁed
three genes, CD10, CD21 and IL2RB, as predictors (Table 3).
Table 2 Signature pathways for DLBCL
Signature pathway Number of annotated genes Nominal P (pathway)a FDR (pathway)b
hsa04640: hematopoietic cell lineage 22 3.80E10 4.76E07
hsa04060: cytokine receptor interaction 24 1.00E06 1.26E03
Note: Signature pathways for DLBCL were identiﬁed by using FDR for multiple tests correction (adjusted a= 0.01). a Modiﬁed Fisher Exact P
value. b FDR stands for false positive rate, which is used for adjustment of multiple tests for 201 pathways. DLBCL stands for diffuse large B-cell
lymphoma.
Figure 2 Clinically distinct DLBCL subtypes deﬁned by gene
expression proﬁling of two signature pathways
Kaplan–Meier plot of the overall survival of the three molecular
subtypes of DLBCL, partitioned using the expression proﬁles of
the genes contained in two signature pathways, hsa04640 and
hsa04060.
34 Genomics Proteomics Bioinformatics 12 (2014) 31–38CD10 encodes a common acute lymphocytic leukemia (ALL)
antigen that serves as an important cell surface marker in the
diagnosis of ALL [24]. CD21 encodes a membrane protein that
functions as a receptor for Epstein–Barr virus (EBV) binding on
B and T lymphocytes. A previous study [25] reported that the
prognosis of CD21-positive DLBCLwas signiﬁcantly favorable
to that of CD21-negative DLBCL and then a later in vivo exper-
iment [26] showed that CD21 was closely related to LFA-1
expression in B-cell lymphoma (BCL), and the absence of
CD21/LFA-1 expression was associated with pleural/peritoneal
ﬂuid involvement caused by BCL, which is a potential indicator
of BCL progression. It is interesting to note that interleukin-2
receptor beta (IL2RB) was signiﬁcant in the Cox propor-
tional-hazards model. Although no study has directly shown
that IL2RB is a predictor for DLBCL, IL2RB has been reported
to be a potential prognostic biomarker for chronic lymphocytic
leukemia (CLL) [27].
Discussion
From a biological perspective, compared to GO that reﬂects
the functional similarities of genes, KEGG pathway reﬂects
an integration of several speciﬁc functions. It is moreTable 3 Multivariate Cox proportional-hazard model built using the g
Variable Estimated coeﬃcient Wa
CD10 0.762 10.6
CD21 0.735 6.21
IL2RB 0.630 6.37
Note: CI stands for conﬁdence interval.systematic in revealing and elucidating the sophisticated
molecular mechanisms underlying complex diseases such as
cancer. Several studies have suggested the link between
cancer subtypes and pathways. Therefore, the proposed
pathway-based clustering approach for unveiling genetic het-
erogeneities of complex diseases would facilitate better
understanding of the mechanisms underlying these phenom-
ena. In this study, we evaluated this approach using a public
benchmark dataset. Our results demonstrated that the gene
expression proﬁles of pathways effectively distinguished
well-characterized clinical types of cancers. Hence, there
was sufﬁcient reason to believe that the putative signature
pathways for a heterogeneous disease could depict the
underlying molecular mechanism(s) leading to the molecular
subtypes. Further application of this proposed pathway-
based approach to DLBCL demonstrated its effectiveness
in dissecting genetic heterogeneities in complex diseases.
Similar to the GO-based approach, the proposed pathway-
based approach is also an efﬁcient unsupervised feature
selection method, which yields multiple feature gene sets
(i.e., genes annotated to identiﬁed signature pathways) of
functional compactness. The genes with top-rank expression
variations across samples were selected as the initial feature
genes [16,17]. Subsequently, the feature genes were further
ﬁltered or organized by signiﬁcant KEGG pathways. Similar
to the GO-based approach, this approach is not only useful
in identifying both the gene expression signatures and the
functional signatures of disease subtypes but can also
provide guidance for functional studies on the molecular
pathogenesis of the diseases investigated.
Although some previous studies [2] that clustered disease
subtypes based on expression proﬁles of the genes achieved
great success in dissecting genetic heterogeneities involved in
DLBCL, such a clustering algorithm itself does not provide
proof of the best grouping of genes in terms of biological func-
tions [28]. Thus, biological interpretation of the grouping
requires expert knowledge, which is often subjective [29]. In
this study, we proposed to directly use an external annotation
database such as the KEGG pathway to extract multiple
functionally compact and coherent gene sets. Three hidden
subtypes were identiﬁed by applying the proposed pathway-
based approach in unraveling DLBCL. In terms of the survival
analysis and the implications of the signature pathways, the
proposed pathway-based approach provided a novel andenes in the two signature pathways
ld v2 P value Hazard ratio (95% CI)
35 0.001 0.530 (0.295–0.738)
0 0.013 0.467 (0.269–0.855)
7 0.012 0.479 (0.327–0.869)
Zhao X et al / Pathway-based Analysis of Heterogeneities 35feasible avenue to the genetic analysis of the hidden subtypes
of complex human diseases such as cancer.
In this study, we took the known cluster number suggested
by the preassigned clinic labels to validate the proposed ap-
proach, assuming the lack of heterogeneities in the NCI60 data
for several well-characterized cancers. Although the clustering
results provided good ﬁts to the known phenotypic partitions,
this assumption might not be true [1]. Meanwhile, the problem
of estimating the correct number of clusters to unveil hidden
cancer subtypes has largely remained unresolved. In addition,
although the proposed pathway-based approach has achieved
some success in the genetic analysis of the underlying molecu-
lar stratiﬁcations in cancer, we should recognize the limitations
of this study. First, only one dataset for DLBCL was analyzed,
it is thus very likely that only a small proportion of the relevant
pathways were identiﬁed due to the limited information pro-
vided by a single dataset. Second, the current knowledge about
pathways is largely fragmented and far from complete; hence,
this limitation would compromise the aspect of this analysis
that relies on pathway knowledge. Finally, although we tried
our best to control type I errors (incorrect rejections of true
null hypotheses) in various steps toward the identiﬁcation of
either pathways or hidden cancer subtypes, whether the overall
type I error was well-controlled remains unclear. In this sense,
we considered our analysis as exploratory in nature. Further
studies using large-scale datasets and reﬁned pathway knowl-
edge are highly demanded, which could increase the effective-
ness in detecting pathways with modest effects. Finally,
although in principle the proposed pathway-based method
for the analysis of genetic heterogeneities could be extended
to other types of data such as that of genome-wide SNPs
and next generation sequencing data, such an approach has
to be carefully assessed. This assessment will be the next focus
of our research group.Materials and methods
Description of datasets
A large classical multiple-class dataset NCI60 [18] was used as
the benchmark dataset to validate the efﬁciency of the pro-
posed pathway-based approach, which consists of 9703
cDNAs measured in 60 cell lines of nine cancers. The data
for prostate cancer were excluded because these consisted of
only two samples. Samples of breast tumors, ovarian cancer
and non-small cell lung carcinoma were also excluded for
the possible existence of heterogeneous hidden subtypes or
misassigned labeling of samples [21,30]. Thus, a subset of the
NCI60 data (35 samples of ﬁve cancer types) was used in
the study, including eight samples of renal cancer (RE), six
samples of central nervous system cancer (CNS), eight samples
of melanoma (ME), seven samples of colon cancer (CO) and
six samples of leukemia (LE). After evaluating its ability for
accurately partitioning this diverse data structure, we used
the proposed pathway-based approach to analyze the hidden
subtypes of DLBCL, which has been demonstrated to be noto-
riously heterogeneous [21,22,30]. The independent dataset for
DLBCL consists of 4026 cDNAs measured in 42 samples [2].
We veriﬁed the identiﬁed hidden partitions by survival analy-
sis of the clinical proﬁles of patients in each molecular-based
partition.A detailed procedure chart for the pathway-based ap-
proach is shown in Figure 3 and described below. The corre-
sponding source code is freely available upon written
request. For data preprocessing, we adopted a uniﬁed criterion
for the initial selection of genes from the previously described
cDNA microarray datasets. First, we discarded clones with
missing data in more than 5% of the arrays and applied a
base-2 logarithmic transformation to the expression data. Sec-
ond, similar to our previous paper [2], we imputed remaining
missing data with zeros. Third, the data for genes were cen-
tered by subtracting the observed median value. The ﬁnal
datasets of NCI60 and DLBCL ﬁnally comprised 5124 and
3148 genes, respectively.
Selecting putative signature pathways from KEGG
For the NCI60 and DLBCL datasets, the top x percent of
genes with largest expression variances were selected as fea-
ture genes. Subsequently, we loaded these feature genes into
the Database for Annotation, Visualization and Integrated
Discovery (DAVID) [31] software to test their enrichment
in pathways based on a modiﬁed Fisher Exact test. Finally,
we identiﬁed the signiﬁcantly enriched pathways at a false
discovery rate (FDR) of 0.01 to adjust for multiple tests of
201 pathways in the DAVID database. To demonstrate the
robustness of the pathways, we compared the pathways iden-
tiﬁed at different top percentage levels (x= 10, 15 and 20) of
the feature genes with the largest variances for NCI60 or
DLBCL.
Clustering samples based on individual pathways
For each signature pathway, we extracted the expression pro-
ﬁles of the measured genes that were annotated to it. By
agglomerative hierarchical clustering algorithm, each sample
was initially assigned to one cluster, then the distances between
clusters were computed, and the two clusters with the smallest
distance value were merged. Distance computation and merg-
ing were repeated until there was only one cluster left. In this
work, correlation (uncentered) was used as the distance metric
and the average linkage method was used for merging. The
software can be downloaded from the website of the Eisen
Lab (http://rana.lbl.gov/EisenSoftware.html). We pruned off
the hierarchical tree to allocate the samples into clusters. To
evaluate the performance of the proposed approach, the num-
ber of clusters in the validation dataset was determined by the
number of predeﬁned clusters from the original data source.
Additionally, we assessed the classiﬁcation performance of
these signature pathways using a decision-tree based approach
[32]. Finally, the adjusted ARI [19] was calculated to measure
the agreement between the identiﬁed clusters and the original
partitions, which ranged from 0 to 1. The expected value of
the ARI is 0 when the partitions are randomly drawn, and
the ARI is 1 when two partitions perfectly agree. A larger
ARI dictates a higher correspondence between two types of
partitions.
To assess the signiﬁcance of the ARI, we compared the
observed ARI value with that of the same-sized gene subsets
randomly selected from the whole microarray. The aim of
this statistical test was to empirically verify whether the
proﬁles of the genes in the signature pathways performed
Data pre-processing
• Discard genes with missing rate > 5%
• Apply a base-2 logarithmic transformation 
• Impute the missing data with 0
• Center each gene with 0 median across samples
Signature pathway selection
• Select the top 10% of genes with largest expression 
variance as feature genes
• Identify signature pathways by enrichment analysis
Sample clustering
• Cluster samples using hierarchical clustering algorithm 
based on individual pathways
• Determine the sample label by multiple pathways
Approach validation
• Calculate ARI
• Build a decision tree
Survival analysis
• Estimate survival curves by Kaplan–Meier
product-limit
• Assess the difference by log-rank test
• Explore clinical predictors by Cox 
proportional-hazards model
Validation dataset
• NCI60 expression data
Application dataset
• DLBCL expression data
Figure 3 A detailed procedure chart for pathway-based analysis of genetic heterogeneities
36 Genomics Proteomics Bioinformatics 12 (2014) 31–38signiﬁcantly better at clustering than the gene groups ran-
domly selected from a null (or contrast) population, in which
the gene had no or less functional relationship. It is well
known that similarly expressed (co-expressed) genes tend to
share the same or similar function(s) and in fact, the gene
co-expression information is often used for predicting gene
functions [33]. Similar to our previous study [1], we con-
structed the null gene population using the silenced genes
among all the annotated genes from the original expression
proﬁles after excluding the genes annotated to the identiﬁed
signature pathways and the genes signiﬁcantly co-expressed
with at least one gene in the signature pathways. Here, two
genes were classiﬁed as co-expressed when the absolute value
of Pearson correlation coefﬁcient of their expression was lar-
ger than a threshold at signiﬁcance level a= 0.005, as deter-
mined using 10,000 gene pairs randomly sampled from the
original expression proﬁles.
Subsequently, for each signature pathway, 1000 gene subsets
of the same gene set size were randomly sampled from the null
population. By applying the same clustering procedure to the
1000 random gene subsets, we deﬁned the empirical P value
for the observed ARI of each signature pathway as the fraction
(proportion) of 1000 random subsets having ARIs larger than
that of the signature pathway. The P value was used to assess
whether an identiﬁed signature pathway had signiﬁcantly better
performance at correctly partitioning the samples (i.e., more
likely relevant to the phenotypic partitions) than the random
gene subsets that were less likely to be functionally related.Clustering based on multiple pathways
The utility of partition for a single pathway might be limited,
wherein some samples could have been misclassiﬁed through
the use of information from only one or a few pathways. To
increase the accuracy of phenotypic partition, we applied a
voting step to comprehensively integrate the partition results
drawn from each signature pathway. Speciﬁcally, for a sample
that had multiple membership labels obtained from different
pathways, we applied a simple majority rule to determine the
sample’s membership. If several classes drew the vote, we ran-
domly assigned one of the class labels to the sample.
The agreement between the clustering results based onmulti-
ple pathways and the original partitions was also evaluated by
calculating the ARI. Alternatively, assuming that the original
phenotypic labels for samples were correct, we evaluated the
signature pathways by building a decision tree [32]. We then
used the approach to unveil the hidden subtypes of DLBCL.
Survival analysis
To verify the clinical signiﬁcance of the identiﬁed hidden
DLBCL subtypes, we estimated the survival curves of the
subtypes using the Kaplan–Meier product-limit method and
assessed the difference between the survival curves using the
log-rank test [34]. To explore a compact model for clinical
use, we also evaluated the potential of genes in the signature
Zhao X et al / Pathway-based Analysis of Heterogeneities 37pathways for predicting phenotypes. First, we applied a uni-
variate Cox proportional-hazards model to identify the genes
whose marginal effects on the overall survival time were signif-
icant. Subsequently, a multivariate Cox proportional-hazards
model was used to analyze the power of the signiﬁcant genes
for predicting the overall survival time. The Wald v2 test was
used to determine the signiﬁcance of each predictor’s hazard
toward the patients’ survival time.
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